/AVTE

AVTE Stock - Aerovate Therapeutics, Inc.

Q: What is the analyst price target for AVTE?

Analyst price target information is not currently available for AVTE.

Q: What is AVTE's market cap?

Market capitalization information is not currently available for AVTE.

Healthcare|Biotechnology|NASDAQ

$2.68+0.00%

+$0.00 (+0.00%) • Apr 28

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+870.1%upside

Target: $26.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AVTE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.95

52W High$884.98

52W Low$2.63

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$-96,000	$-68,000	$-15,000	$-1,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-74,596,000	$-81,409,000	$-53,237,000	$-23,022,000	$-8,889,000
Net Income	$-69,628,000	$-75,521,000	$-51,511,000	$-22,963,000	$-9,611,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.44	$-2.87	$-2.10	$-1.87	$-40.17

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

36%

Hold / Neutral

64%

Sell / Underperform

Analyst Consensus🔴 Bearish

4 Bullish7 Neutral/Bearish

Price Targets

$25

Average Target

↑ 818.8% Upside

Now

Low

$25

Average

$65

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
June 18th 2024	Evercore ISI	Downgrade	In-line	$2← $27
June 18th 2024	TD Cowen	Downgrade	Hold	-
June 18th 2024	Wells Fargo	Downgrade	Equal Weight	$2← $35
June 17th 2024	Guggenheim	Downgrade	Neutral	-
June 17th 2024	BTIG Research	Downgrade	Neutral	-
June 17th 2024	Wedbush	Downgrade	Neutral	$3← $41
March 25th 2024	Jefferies	Resumed	Buy	$65← $21
December 8th 2023	Wells Fargo	Initiation	Equal Weight	$35
March 1st 2023	Guggenheim	Initiation	Buy	$36
December 6th 2022	BTIG Research	Upgrade	Buy	$27
September 19th 2022	Wedbush	Resumed	Outperform	$27
August 16th 2022	BTIG Research	Downgrade	Neutral	-

Earnings History & Surprises

AVTE

Beat Rate

18%

Last 17 quarters

Avg Surprise

-890.2%

EPS vs Estimate

Beats / Misses

3/12

2 met exactly

Latest EPS

$-0.64

Q4 2025

EPS Surprise History

Q1 24

-8.8%

$-0.74vs$-0.68

Q2 24

-12.2%

$-0.83vs$-0.74

Q3 24

-13.2%

$-0.86vs$-0.76

Q4 24

+5.1%

$-0.56vs$-0.59

Q1 25

0.0%

$-0.19vs$-0.19

Q2 25

+70.0%

$-0.09vs$-0.30

Q3 25

-352.1%

$-1.13vs$-0.25

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 10, 2025	—	$-0.64	—	—
Q3 2025	Aug 11, 2025	$-0.25	$-1.13	-352.1%	✗ MISS
Q2 2025	Apr 25, 2025	$-0.30	$-0.09	+70.0%	✓ BEAT
Q1 2025	Mar 27, 2025	$-0.19	$-0.19	0.0%	= MET
Q4 2024	Nov 12, 2024	$-0.59	$-0.56	+5.1%	✓ BEAT
Q3 2024	Aug 12, 2024	$-0.76	$-0.86	-13.2%	✗ MISS
Q2 2024	May 13, 2024	$-0.74	$-0.83	-12.2%	✗ MISS
Q1 2024	Mar 25, 2024	$-0.68	$-0.74	-8.8%	✗ MISS
Q4 2023	Nov 13, 2023	$-0.70	$-0.71	-1.4%	✗ MISS
Q3 2023	Aug 14, 2023	$-0.69	$-0.76	-10.1%	✗ MISS
Q2 2023	May 15, 2023	$-0.58	$-0.67	-15.5%	✗ MISS
Q1 2023	Mar 29, 2023	$-0.58	$-0.61	-5.2%	✗ MISS
Q4 2022	Nov 14, 2022	$-0.50	$-0.56	-12.0%	✗ MISS
Q3 2022	Aug 15, 2022	$-0.46	$-0.49	-6.5%	✗ MISS
Q2 2022	May 16, 2022	$-0.26	$-0.45	-73.1%	✗ MISS
Q1 2022	Mar 30, 2022	$-0.31	$-0.07	+77.4%	✓ BEAT
Q4 2021	Nov 15, 2021	$-0.26	$-0.26	0.0%	= MET
Q3 2021	Aug 16, 2021	$-0.16	$-23.80	-14775.0%	✗ MISS
Q2 2021	Jun 30, 2021	—	$-15.08	—	—
Q1 2021	Mar 31, 2021	—	$-0.13	—	—

Frequently Asked Questions about AVTE

What is AVTE's current stock price?

Aerovate Therapeutics, Inc. (AVTE) is currently trading at $2.68 per share. The stock has moved +0.00% today.

What is the analyst price target for AVTE?

The average analyst price target for AVTE is $26.00, based on 1 analyst.

What sector is Aerovate Therapeutics, Inc. in?

Aerovate Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AVTE's market cap?

Aerovate Therapeutics, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.

Does AVTE pay dividends?

No, Aerovate Therapeutics, Inc. does not currently pay a dividend to shareholders.